133 related articles for article (PubMed ID: 1458697)
1. Antiphospholipid antibodies and complement activation in patients with cerebral ischemia.
Davis WD; Brey RL
Clin Exp Rheumatol; 1992; 10(5):455-60. PubMed ID: 1458697
[TBL] [Abstract][Full Text] [Related]
2. Antiphospholipid antibody carriers and patients with quiescent antiphospholipid syndrome show persistent subclinical complement activation.
Zen M; Tonello M; Favaro M; Del Ross T; Calligaro A; Giollo A; Vesentini F; Gennaio IA; Arru F; Ruffatti A; Doria A
Rheumatology (Oxford); 2024 May; 63(6):1733-1738. PubMed ID: 37774001
[TBL] [Abstract][Full Text] [Related]
3. Complement activation predicts adverse pregnancy outcome in patients with systemic lupus erythematosus and/or antiphospholipid antibodies.
Kim MY; Guerra MM; Kaplowitz E; Laskin CA; Petri M; Branch DW; Lockshin MD; Sammaritano LR; Merrill JT; Porter TF; Sawitzke A; Lynch AM; Buyon JP; Salmon JE
Ann Rheum Dis; 2018 Apr; 77(4):549-555. PubMed ID: 29371202
[TBL] [Abstract][Full Text] [Related]
4. SC5b-9 is the most sensitive marker in assessing disease activity in Brazilian SLE patients.
Chiu YY; Nisihara RM; Würzner R; Kirschfink M; de Messias-Reason IJ
J Investig Allergol Clin Immunol; 1998; 8(4):239-44. PubMed ID: 9777539
[TBL] [Abstract][Full Text] [Related]
5. Complement activation in patients with isolated antiphospholipid antibodies or primary antiphospholipid syndrome.
Breen KA; Seed P; Parmar K; Moore GW; Stuart-Smith SE; Hunt BJ
Thromb Haemost; 2012 Mar; 107(3):423-9. PubMed ID: 22234447
[TBL] [Abstract][Full Text] [Related]
6. Complement components and their activation products in pleural fluid.
Salomaa ER; Viander M; Saaresranta T; Terho EO
Chest; 1998 Sep; 114(3):723-30. PubMed ID: 9743157
[TBL] [Abstract][Full Text] [Related]
7. Complement activation during CAPD.
Young GA; Kendall S; Brownjohn AM
Nephrol Dial Transplant; 1993; 8(12):1372-5. PubMed ID: 8159307
[TBL] [Abstract][Full Text] [Related]
8. Levels of complement components iC3b, C3c, C4, and SC5b-9 in peritoneal fluid and serum of infertile women with endometriosis.
Kabut J; Kondera-Anasz Z; Sikora J; Mielczarek-Palacz A
Fertil Steril; 2007 Nov; 88(5):1298-303. PubMed ID: 17482181
[TBL] [Abstract][Full Text] [Related]
9. Levels of SC5b--9 complement complex in plasma and synovial fluid of patients with rheumatic disease.
Rus V; Malide D; Boloşiu HD; Parasca I; Duţu AL
Med Interne; 1990; 28(4):305-10. PubMed ID: 2100875
[TBL] [Abstract][Full Text] [Related]
10. Complement activation: a novel pathogenic mechanism in the antiphospholipid syndrome.
Pierangeli SS; Vega-Ostertag M; Liu X; Girardi G
Ann N Y Acad Sci; 2005 Jun; 1051():413-20. PubMed ID: 16126983
[TBL] [Abstract][Full Text] [Related]
11. Antiphospholipid antibodies in neonates with stroke--a unique entity or variant of antiphospholipid syndrome?
Berkun Y; Simchen MJ; Strauss T; Menashcu S; Padeh S; Kenet G
Lupus; 2014 Sep; 23(10):986-93. PubMed ID: 24729280
[TBL] [Abstract][Full Text] [Related]
12. Clinical manifestations of the antiphospholipid syndrome in patients with systemic lupus erythematosus associate more strongly with anti-beta 2-glycoprotein-I than with antiphospholipid antibodies.
Cabiedes J; Cabral AR; Alarcón-Segovia D
J Rheumatol; 1995 Oct; 22(10):1899-906. PubMed ID: 8991989
[TBL] [Abstract][Full Text] [Related]
13. Usefulness of detection of complement activation products in evaluating SLE activity.
Nagy G; Brózik M; Varga L; Füst G; Kirschfink M; Kiss E; Gergely P
Lupus; 2000; 9(1):19-25. PubMed ID: 10713643
[TBL] [Abstract][Full Text] [Related]
14. Requirement of activation of complement C3 and C5 for antiphospholipid antibody-mediated thrombophilia.
Pierangeli SS; Girardi G; Vega-Ostertag M; Liu X; Espinola RG; Salmon J
Arthritis Rheum; 2005 Jul; 52(7):2120-4. PubMed ID: 15986360
[TBL] [Abstract][Full Text] [Related]
15. Strong complement activation after acute ischemic stroke is associated with unfavorable outcomes.
Széplaki G; Szegedi R; Hirschberg K; Gombos T; Varga L; Karádi I; Entz L; Széplaki Z; Garred P; Prohászka Z; Füst G
Atherosclerosis; 2009 May; 204(1):315-20. PubMed ID: 18804761
[TBL] [Abstract][Full Text] [Related]
16. Antiphospholipid antibodies and ischemic stroke.
Brey RL
Heart Dis Stroke; 1992; 1(6):379-82. PubMed ID: 1344135
[TBL] [Abstract][Full Text] [Related]
17. Demonstration of apoptosis-associated cleavage products of DNA, complement activation products SC5b-9 and C3d/dg, and immune complexes CIC-C3d, CIC-IgA, and CIC-IgG in the urine of patients with membranous glomerulonephritis.
Kotnik V; Premzl A; Skoberne M; Malovrh T; Kveder R; Kaplan-Pavlovcic S; Kotnik A; Stiblar-Martincic D
Croat Med J; 2003 Dec; 44(6):707-11. PubMed ID: 14652883
[TBL] [Abstract][Full Text] [Related]
18. Activation of terminal components of complement in patients with Guillain-Barré syndrome and other demyelinating neuropathies.
Koski CL; Sanders ME; Swoveland PT; Lawley TJ; Shin ML; Frank MM; Joiner KA
J Clin Invest; 1987 Nov; 80(5):1492-7. PubMed ID: 3680509
[TBL] [Abstract][Full Text] [Related]
19. Autoantibodies to beta2-glycoprotein I in systemic lupus erythematosus and primary antiphospholipid antibody syndrome: clinical correlations in comparison with other antiphospholipid antibody tests.
Day HM; Thiagarajan P; Ahn C; Reveille JD; Tinker KF; Arnett FC
J Rheumatol; 1998 Apr; 25(4):667-74. PubMed ID: 9558167
[TBL] [Abstract][Full Text] [Related]
20. [ELISA for detection of SC5b-9 levels in plasma and its clinical significance in SLE disease].
Kan D
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1993 Aug; 15(4):302-5. PubMed ID: 8168211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
